Comparative Study on the Therapeutic Outcomes of Enzalutamide Combined with Docetaxel Versus Docetaxel Alone in Metastatic Castration-Resistant Prostate Cancer Patients Following Sequential Androgen Receptor Pathway Targeted Therapy Failure

To evaluate the therapeutic effectiveness and adverse effects of combining enzalutamide with docetaxel versus using docetaxel alone in treating metastatic castration-resistant prostate cancer (mCRPC) that progresses after effective treatment with abiraterone followed by enzalutamide.

本数据集旨在评估恩扎卢胺(enzalutamide)联合多西他赛(docetaxel)，与单用多西他赛相比，在治疗经阿比特龙(abiraterone)序贯恩扎卢胺有效治疗后进展的转移性去势抵抗性前列腺癌(mCRPC)时的治疗效果与不良反应。